Stock comparison
IDEXX Laboratories
Pharming Group N.V.
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
PHAR
Pharming Group N.V.
Market cap
$889.88M
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | PHAR | Winner |
|---|---|---|---|
| Warren Buffett | 75B | 37D | IDXX |
| Benjamin Graham | 80A | 67D | IDXX |
| Philip Fisher | 75B | 43D | IDXX |
| Peter Lynch | 71B | 25F | IDXX |
| Joel Greenblatt | 83C | 44D | IDXX |
| Charlie Munger | 87A | 34F | IDXX |
| Terry Smith | 84A | 41D | IDXX |
Side-by-side metrics
| Metric | IDXX | PHAR |
|---|---|---|
| Market cap | $44.12B | $889.88M |
| P/E (TTM) | 39.0x | 77.6x |
| EV/EBIT | 31.6x | 50.7x |
| ROIC (TTM) | 40.66% | 3.76% |
| Gross margin | 62.05% | 88.12% |
| Net margin | 24.63% | 3.37% |
| Revenue CAGR 5y | 7.56% | 17.35% |
| EPS CAGR 5y | 10.79% | -33.13% |
| Debt / Equity | 0.7x | 0.4x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- EPS CAGR 5y10.79%vs -33.13%+133%
- Market cap$44.12Bvs $889.88M+98%
- ROIC (TTM)40.66%vs 3.76%+91%
- Net margin24.63%vs 3.37%+86%
PHAR leads on
- Revenue CAGR 5y17.35%vs 7.56%+56%
- Debt / Equity0.4xvs 0.7x+38%
- Gross margin88.12%vs 62.05%+30%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.